Bicara Therapeutics (NASDAQ:BCAX) Coverage Initiated by Analysts at Wedbush

Research analysts at Wedbush initiated coverage on shares of Bicara Therapeutics (NASDAQ:BCAX) in a research report issued on Thursday,Briefing.com Automated Import reports. The brokerage set an “outperform” rating and a $31.00 price target on the stock. Wedbush’s price target would indicate a potential upside of 143.71% from the company’s current price.

A number of other research firms have also recently commented on BCAX. HC Wainwright boosted their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Finally, Rodman & Renshaw assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price target on the stock. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Bicara Therapeutics currently has an average rating of “Buy” and an average target price of $41.20.

Bicara Therapeutics Stock Performance

NASDAQ BCAX opened at $12.72 on Thursday. The stock’s fifty day moving average price is $16.00. Bicara Therapeutics has a 52 week low of $11.10 and a 52 week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last posted its earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). As a group, equities research analysts anticipate that Bicara Therapeutics will post -2.59 earnings per share for the current year.

Institutional Trading of Bicara Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of BCAX. First Turn Management LLC acquired a new stake in shares of Bicara Therapeutics during the third quarter worth $14,324,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Bicara Therapeutics during the third quarter worth $582,000. FMR LLC acquired a new stake in shares of Bicara Therapeutics during the third quarter worth $57,913,000. Walleye Capital LLC acquired a new stake in shares of Bicara Therapeutics during the third quarter worth $809,000. Finally, Vestal Point Capital LP bought a new position in shares of Bicara Therapeutics during the third quarter worth about $10,825,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.